Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio di Fase III di HMPL-760 in combinazione con R-GemOx rispetto a placebo in combinazione con R-GemOx nel DLBCL recidivato/refrattario

9 novembre 2026 aggiornato da: Hutchmed

Uno Studio di Fase III Randomizzato, in Doppio Cieco, Controllato Positivo per Valutare l'Efficacia, la Sicurezza e la Farmacocinetica di HMPL-760 in Combinazione con R-GemOx Rispetto al Placebo in Combinazione con R-GemOx in Pazienti con Linfoma Diffuso a Grandi Cellule B (DLBCL) Recidivato/Refrattario

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Panoramica dello studio

Descrizione dettagliata

The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

The target population of this study includes patients with DLBCL who are relapsed or refractory.

Tipo di studio

Interventistico

Iscrizione (Stimato)

240

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Baoding, Cina
        • Reclutamento
        • Baoding NO.1 Central Hospital
        • Contatto:
        • Investigatore principale:
          • Haiying Yao
      • Beijing, Cina
        • Reclutamento
        • Beijing GoBroad Hospital
        • Investigatore principale:
          • Kai Hu
        • Contatto:
      • Beijing, Cina
        • Reclutamento
        • BEIJING TONGREN HOSPITAL, Capital Medical University
        • Investigatore principale:
          • Liang Wang
        • Contatto:
      • Bengbu, Cina
        • Reclutamento
        • The First Affiliated Hospital of Bengbu Medical College
        • Contatto:
        • Investigatore principale:
          • Yanli Yang
      • Changchun, Cina
        • Reclutamento
        • The First Hospital of Jilin University
        • Investigatore principale:
          • Ou Bai
        • Contatto:
      • Changsha, Cina
        • Reclutamento
        • Hunan Cancer Hospital
        • Investigatore principale:
          • Hui Zhou
        • Contatto:
      • Changsha, Cina
        • Reclutamento
        • The Second Xiangya Hospital of Central South University
        • Investigatore principale:
          • Hongling Peng
        • Contatto:
      • Changsha, Cina
        • Reclutamento
        • People's Hospital of Hunan Province
        • Contatto:
        • Investigatore principale:
          • Can Liu
      • Chengdu, Cina
        • Reclutamento
        • West China Hospital of Sichuan University
        • Investigatore principale:
          • Liqun Zou
        • Contatto:
      • Chengdu, Cina
        • Reclutamento
        • Sichuan Provincial People's Hospital
        • Contatto:
        • Investigatore principale:
          • Xiaobing Huang
      • Chongqing, Cina
        • Reclutamento
        • The First Affiliated Hospital of Chongqing Medical University
        • Investigatore principale:
          • Xin Wang
        • Contatto:
      • Chongqing, Cina
        • Reclutamento
        • Chongqing University Cancer Hospital
        • Investigatore principale:
          • Yao Liu
        • Contatto:
      • Fujian, Cina
        • Reclutamento
        • Quanzhou First Hospital.Fujian
        • Contatto:
        • Investigatore principale:
          • Xiongpeng Zhu
      • Fuzhou, Cina
        • Reclutamento
        • Fujian Medical University Union Hospital
        • Investigatore principale:
          • Jianzhen Shen
        • Contatto:
      • Guangzhou, Cina
        • Reclutamento
        • Sun Yat-sen University Cancer Center
        • Investigatore principale:
          • Zhiming Li
        • Contatto:
      • Guangzhou, Cina
        • Reclutamento
        • Guangdong Provincial People's Hospital
        • Contatto:
        • Investigatore principale:
          • Xiaojuan Wei
      • Guangzhou, Cina
        • Reclutamento
        • ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
        • Investigatore principale:
          • Yuhua Li
        • Contatto:
      • Guiyang, Cina
        • Reclutamento
        • The Affiliated Hospital of Guizhou Medical University
        • Investigatore principale:
          • Yan Zhang
        • Contatto:
      • Hangzhou, Cina
        • Reclutamento
        • Zhejiang Cancer Hospital
        • Investigatore principale:
          • Haiyan Yang
        • Contatto:
      • Hangzhou, Cina
        • Reclutamento
        • The First Affiliated Hospital, Zhejiang University
        • Investigatore principale:
          • Zhen Cai
        • Contatto:
      • Harbin, Cina
        • Reclutamento
        • Harbin Medical University Cancer Hospital
        • Contatto:
        • Investigatore principale:
          • Qingyuan Zhang
      • Hefei, Cina
        • Reclutamento
        • The Second Affiliated Hospital of Anhui Medical University
        • Contatto:
        • Investigatore principale:
          • Zhimin Zhai
      • Jinan, Cina
        • Reclutamento
        • Qilu Hospital of Shandong University
        • Contatto:
        • Investigatore principale:
          • Shuqian Xu
      • Jinan, Cina
        • Reclutamento
        • Shandong Cancer Hospital & Institute
        • Investigatore principale:
          • Zengjun Li
        • Contatto:
      • Kunming, Cina
        • Non ancora reclutamento
        • The First Affiliated Hospital of Kunming Medical University
        • Contatto:
        • Investigatore principale:
          • Mingxia Shi
      • Nanchang, Cina
        • Reclutamento
        • Jiangxi Cancer Hospital
        • Investigatore principale:
          • Yan Huang
        • Contatto:
      • Nanjing, Cina
        • Reclutamento
        • Jiangsu Cancer Hospital
        • Investigatore principale:
          • Yan Zhang
        • Contatto:
      • Nanjing, Cina
        • Reclutamento
        • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
        • Contatto:
        • Investigatore principale:
          • Jingyan Xu
      • Nanning, Cina
        • Reclutamento
        • The First Affiliated Hospital of Guangxi Medical University
        • Investigatore principale:
          • Zhigang Peng
        • Contatto:
      • Qingdao, Cina
        • Reclutamento
        • The Affiliated Hospital of Qingdao University
        • Contatto:
        • Investigatore principale:
          • Xia Zhao
      • Shanghai, Cina
        • Reclutamento
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Investigatore principale:
          • Weili Zhao
        • Contatto:
      • Shanghai, Cina
        • Reclutamento
        • Tongji Hospital of Tongji University
        • Contatto:
        • Investigatore principale:
          • Ping Li
      • Shanghai, Cina
        • Non ancora reclutamento
        • Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
        • Investigatore principale:
          • Ligen Liu
        • Contatto:
      • Shenyang, Cina
        • Reclutamento
        • Shengjing Hospital of China Medical University
        • Investigatore principale:
          • Wei Yang
        • Contatto:
      • Shenzhen, Cina
        • Reclutamento
        • Shenzhen people's hospital
        • Investigatore principale:
          • Jihao Zhou
        • Contatto:
      • Taiyuan, Cina
        • Reclutamento
        • Shanxi Provincial Cancer Hospital
        • Investigatore principale:
          • Liping Su
        • Contatto:
      • Tangshan, Cina
        • Reclutamento
        • North China University of Science and Technology Affiliated Hospital
        • Contatto:
        • Investigatore principale:
          • Zhenyu Yan
      • Tianjin, Cina
        • Reclutamento
        • Tianjin Medical University Cancer Institute & Hospital
        • Investigatore principale:
          • Zhengzi Qian
        • Contatto:
          • Zhengzi Qian
          • Numero di telefono: 13702031222
          • Email: qzz@163.com
      • Tianjin, Cina
        • Reclutamento
        • Tianjin People's Hospital
        • Contatto:
        • Investigatore principale:
          • Xingli Zhao
      • Tianjin, Cina
        • Reclutamento
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
        • Investigatore principale:
          • Dehui Zou
        • Contatto:
      • Wenzhou, Cina
        • Reclutamento
        • The First Affiliated Hospital of WMU
        • Contatto:
        • Investigatore principale:
          • Songfu Jiang
      • Wuhan, Cina
        • Reclutamento
        • Hubei Cancer Hospital
        • Investigatore principale:
          • Huijing Wu
        • Contatto:
      • Wuhan, Cina
        • Reclutamento
        • Wuhan Union Hospital of China
        • Investigatore principale:
          • Liling Zhang
        • Contatto:
      • Xi'an, Cina
        • Reclutamento
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Investigatore principale:
          • Pengcheng He
        • Contatto:
      • Xi'an, Cina
        • Reclutamento
        • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
        • Investigatore principale:
          • Jie Liu
        • Contatto:
      • Xiamen, Cina
        • Non ancora reclutamento
        • The First Affiliated Hospital of Xiamen University
        • Investigatore principale:
          • Bing Xu
        • Contatto:
      • Xuzhou, Cina
        • Reclutamento
        • The Affiliated Hospital of Xuzhou Medical University
        • Contatto:
        • Investigatore principale:
          • Wei Sang
      • Zhengzhou, Cina
        • Reclutamento
        • Henan Cancer Hospital
        • Investigatore principale:
          • Keshu Zhou
        • Contatto:
      • Zhengzhou, Cina
        • Reclutamento
        • The First Affiliated Hospital of Zhengzhou University
        • Contatto:
        • Investigatore principale:
          • Xudong Zhang
      • Ürümqi, Cina
        • Reclutamento
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • Investigatore principale:
          • Yan Li
        • Contatto:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina
        • Reclutamento
        • Fudan University Shanghai Cancer Center
        • Contatto:
        • Investigatore principale:
          • Fangfang Lv

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Sign the ICF and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. ECOG performance status score between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally measurable lesion;
  7. Expected survival is more than 12 weeks;

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
  8. Clinically significant active infection;

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: The experimental group

Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Patients will receive HMPL-760 once daily (QD) orally.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Altri nomi:
  • Gemcitabina cloridrato per iniezione
  • Iniezione di Rituximab
  • Iniezione di Oxaliplatino
Comparatore placebo: The control group

Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Altri nomi:
  • Gemcitabina cloridrato per iniezione
  • Iniezione di Rituximab
  • Iniezione di Oxaliplatino

Patients will receive HMPL-760 placebo once daily (QD) orally.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Progression-free survival (PFS)
Lasso di tempo: Up to approximately two years

Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first.

Up to approximately two years
End of treatment (EOT)
Lasso di tempo: Up to approximately two years

Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy).

Up to approximately two years
Systemic antitumor therapy
Lasso di tempo: Up to approximately two years

Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy).

Up to approximately two years
Overall survival (OS)
Lasso di tempo: Up to approximately two years

OS is defined as the time from randomization to death due to any cause.

Up to approximately two years
systematic anti-tumor therapy
Lasso di tempo: Up to approximately two years

OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy).

Up to approximately two years
Premature withdrawal from study treatment
Lasso di tempo: Up to approximately two years

OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy).

Up to approximately two years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Independent review committee (IRC)-assessed PFS
Lasso di tempo: Up to approximately two years

Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).

Up to approximately two years
IRC- and investigator-assessed objective response rate (ORR)
Lasso di tempo: Up to approximately two years

Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR)

Up to approximately two years
IRC- and investigator-assessed complete response rate (CRR)
Lasso di tempo: Up to approximately two years

Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR)

Up to approximately two years
IRC- and investigator-assessed duration of response (DoR)
Lasso di tempo: Up to approximately two years

For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first

Up to approximately two years
IRC- and investigator-assessed clinical benefit rate (CBR)
Lasso di tempo: Up to approximately two years

Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD)

Up to approximately two years
IRC- and investigator-assessed time to response (TTR)
Lasso di tempo: Up to approximately two years

Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR)

Up to approximately two years
Safety Endpoints
Lasso di tempo: Up to approximately two years
  • Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious adverse events (TESAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 (NCI CTCAE 6.0).
  • Changes in laboratory tests, vital signs, 12-lead ECG, etc.
Up to approximately two years
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Lasso di tempo: At the end of Cycle 4 (each cycle is 21 days)]

including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

At the end of Cycle 4 (each cycle is 21 days)]

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Biomarker assessment
Lasso di tempo: Up to approximately two years

Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy.

Up to approximately two years
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Lasso di tempo: Up to approximately two years

Human metabolites of HMPL-760 when co-administered with R-GemOx

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Lasso di tempo: Up to approximately two years

maximum concentration in steady-state (Cmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Lasso di tempo: Up to approximately two years

time to maximum concentration in steady-state (Tmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Lasso di tempo: Up to approximately two years

Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Lasso di tempo: Up to approximately two years

The rate at which the drug is eliminated from the body (CL/F) (if applicable )

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Lasso di tempo: Up to approximately two years

The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable)

Up to approximately two years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Weili Zhao, Ruijin Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

20 marzo 2026

Completamento primario (Stimato)

30 aprile 2028

Completamento dello studio (Stimato)

30 dicembre 2028

Date di iscrizione allo studio

Primo inviato

28 gennaio 2026

Primo inviato che soddisfa i criteri di controllo qualità

6 febbraio 2026

Primo Inserito (Effettivo)

13 febbraio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi